The decrease of CD4/CD8 ratio in the blood due to the increased level of CD8+ is considered a marker for a number of tumors, that is, of particular significance for pSS which is associated with the highest risk of developing lymphoproliferative diseases compared to sSS, RA, SLE, or other systemic connective tissue diseases [43]. The gene discussed is CD8A; the disease is systemic lupus erythematosus.